CD274 and neoplasm: Considering the cost-effectiveness of ICB, baseline SAR, hNLR, and history of RT in addition to the molecular nature of the tumor (i.e., MSI-H, MSS, EBV, and PD-L1 status) could be considered for proper patient selection in clinical practice.